Investigators from Colombia and Ecuador reported that the prevalence of dry eye disease (DED)-related symptoms in South America “is notably higher than global averages, highlighting regional challenges,”1 according to first author Valentina Loaiza-Guevara from the Facultad de Medicina, Fundación Universitaria Autónoma de las Americas, Pereira, Colombia.The authors explained … [Read more...] about Prevalence of dry eye disease-related symptoms higher in South America
News
Innovation Series: How DMEI residents are shaping the future with smartphone imaging for retinal care (part 2)
In this second of an exclusive three-part Ophthalmology Times EyePod podcast series on innovation, we continue our discussion with Jibran Sharieff, MD (PGY-2), and Brandon Kingrey, MD (PGY-3), who are residents at the Dean McGee Eye Institute (DMEI)/University of Oklahoma Department of Ophthalmology in Oklahoma City. They recently won second place at the Eyecelerator … [Read more...] about Innovation Series: How DMEI residents are shaping the future with smartphone imaging for retinal care (part 2)
Effects and safety of combined corneal collagen crosslinking and intrastromal corneal ring segment treatment in patients with keratoconus: a retrospective study
To evaluate the safety and efficacy of different time-point combinations of intrastromal corneal ring segment (ICRS) implantation using femtosecond technology) and corneal collagen crosslinking (CXL) for the t... … [Read more...] about Effects and safety of combined corneal collagen crosslinking and intrastromal corneal ring segment treatment in patients with keratoconus: a retrospective study
Case #70: Boucher-Neuhauser Syndrome: 5 Decades of Persistence – Page 19 of 19
Background 55 y/o M with complaints of blurred vision after each cancer treatment that resolves within a few days. He had two prior cycles of treatment and experienced the same vision symptoms each time. PMH: Recurrent cutaneous melanoma on dabrafenib (BRAF Inhibitor) and trametinib (MEK Inhibitor) .fusion-fullwidth.fusion-builder-row-1 … [Read more...] about Case #70: Boucher-Neuhauser Syndrome: 5 Decades of Persistence – Page 19 of 19
Case #70: Boucher-Neuhauser Syndrome: 5 Decades of Persistence – Page 18 of 19
Background 55 y/o M with complaints of blurred vision after each cancer treatment that resolves within a few days. He had two prior cycles of treatment and experienced the same vision symptoms each time. PMH: Recurrent cutaneous melanoma on dabrafenib (BRAF Inhibitor) and trametinib (MEK Inhibitor) .fusion-fullwidth.fusion-builder-row-2 … [Read more...] about Case #70: Boucher-Neuhauser Syndrome: 5 Decades of Persistence – Page 18 of 19
Case #70: Boucher-Neuhauser Syndrome: 5 Decades of Persistence – Page 17 of 19
Background 55 y/o M with complaints of blurred vision after each cancer treatment that resolves within a few days. He had two prior cycles of treatment and experienced the same vision symptoms each time. PMH: Recurrent cutaneous melanoma on dabrafenib (BRAF Inhibitor) and trametinib (MEK Inhibitor) .fusion-fullwidth.fusion-builder-row-3 … [Read more...] about Case #70: Boucher-Neuhauser Syndrome: 5 Decades of Persistence – Page 17 of 19
Case #70: Boucher-Neuhauser Syndrome: 5 Decades of Persistence – Page 16 of 19
Background 55 y/o M with complaints of blurred vision after each cancer treatment that resolves within a few days. He had two prior cycles of treatment and experienced the same vision symptoms each time. PMH: Recurrent cutaneous melanoma on dabrafenib (BRAF Inhibitor) and trametinib (MEK Inhibitor) .fusion-fullwidth.fusion-builder-row-4 … [Read more...] about Case #70: Boucher-Neuhauser Syndrome: 5 Decades of Persistence – Page 16 of 19
Case #70: Boucher-Neuhauser Syndrome: 5 Decades of Persistence – Page 15 of 19
Background 55 y/o M with complaints of blurred vision after each cancer treatment that resolves within a few days. He had two prior cycles of treatment and experienced the same vision symptoms each time. PMH: Recurrent cutaneous melanoma on dabrafenib (BRAF Inhibitor) and trametinib (MEK Inhibitor) .fusion-fullwidth.fusion-builder-row-5 … [Read more...] about Case #70: Boucher-Neuhauser Syndrome: 5 Decades of Persistence – Page 15 of 19
Case #70: Boucher-Neuhauser Syndrome: 5 Decades of Persistence – Page 14 of 19
Background 55 y/o M with complaints of blurred vision after each cancer treatment that resolves within a few days. He had two prior cycles of treatment and experienced the same vision symptoms each time. PMH: Recurrent cutaneous melanoma on dabrafenib (BRAF Inhibitor) and trametinib (MEK Inhibitor) .fusion-fullwidth.fusion-builder-row-6 … [Read more...] about Case #70: Boucher-Neuhauser Syndrome: 5 Decades of Persistence – Page 14 of 19
Case #70: Boucher-Neuhauser Syndrome: 5 Decades of Persistence – Page 13 of 19
Background 55 y/o M with complaints of blurred vision after each cancer treatment that resolves within a few days. He had two prior cycles of treatment and experienced the same vision symptoms each time. PMH: Recurrent cutaneous melanoma on dabrafenib (BRAF Inhibitor) and trametinib (MEK Inhibitor) .fusion-fullwidth.fusion-builder-row-7 … [Read more...] about Case #70: Boucher-Neuhauser Syndrome: 5 Decades of Persistence – Page 13 of 19